Quality of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus

Haley K. Holmer, Lauren A. Ogden, Brittany U. Burda, Susan L. Norris

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: Several studies have reported that clinical practice guidelines (CPGs) in a variety of clinical areas are of modest or variable quality. The objective of this study was to evaluate the quality of an international cohort of CPGs that provide recommendations on pharmaceutical management of glycemic control in patients with type 2 diabetes mellitus (DM2). Methods and Findings: We searched the National Guideline Clearinghouse (NGC) on February 15th and June 4th, 2012 for CPGs meeting inclusion criteria. Two independent assessors rated the quality of each CPG using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument. Twenty-four guidelines were evaluated, and most had high scores for clarity and presentation. However, scope and purpose, stakeholder involvement, rigor of development, and applicability domains varied considerably. The majority of guidelines scored low on editorial independence, and only seven CPGs were based on an underlying systematic review of the evidence. Conclusions: The overall quality of CPGs for glycemic control in DM2 is moderate, but there is substantial variability among quality domains within and across guidelines. Guideline users need to be aware of this variability and carefully appraise and select the guidelines that they apply to patient care.

Original languageEnglish (US)
Article numbere58625
JournalPLoS One
Volume8
Issue number4
DOIs
StatePublished - Apr 5 2013

Fingerprint

glycemic control
Medical problems
Practice Guidelines
noninsulin-dependent diabetes mellitus
Type 2 Diabetes Mellitus
Guidelines
Pharmaceutical Preparations
Patient Care
patient care
systematic review
stakeholders
Research

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Quality of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus. / Holmer, Haley K.; Ogden, Lauren A.; Burda, Brittany U.; Norris, Susan L.

In: PLoS One, Vol. 8, No. 4, e58625, 05.04.2013.

Research output: Contribution to journalArticle

Holmer, Haley K. ; Ogden, Lauren A. ; Burda, Brittany U. ; Norris, Susan L. / Quality of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus. In: PLoS One. 2013 ; Vol. 8, No. 4.
@article{620316af67b8430a9c019502909115b3,
title = "Quality of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus",
abstract = "Background: Several studies have reported that clinical practice guidelines (CPGs) in a variety of clinical areas are of modest or variable quality. The objective of this study was to evaluate the quality of an international cohort of CPGs that provide recommendations on pharmaceutical management of glycemic control in patients with type 2 diabetes mellitus (DM2). Methods and Findings: We searched the National Guideline Clearinghouse (NGC) on February 15th and June 4th, 2012 for CPGs meeting inclusion criteria. Two independent assessors rated the quality of each CPG using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument. Twenty-four guidelines were evaluated, and most had high scores for clarity and presentation. However, scope and purpose, stakeholder involvement, rigor of development, and applicability domains varied considerably. The majority of guidelines scored low on editorial independence, and only seven CPGs were based on an underlying systematic review of the evidence. Conclusions: The overall quality of CPGs for glycemic control in DM2 is moderate, but there is substantial variability among quality domains within and across guidelines. Guideline users need to be aware of this variability and carefully appraise and select the guidelines that they apply to patient care.",
author = "Holmer, {Haley K.} and Ogden, {Lauren A.} and Burda, {Brittany U.} and Norris, {Susan L.}",
year = "2013",
month = "4",
day = "5",
doi = "10.1371/journal.pone.0058625",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Quality of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus

AU - Holmer, Haley K.

AU - Ogden, Lauren A.

AU - Burda, Brittany U.

AU - Norris, Susan L.

PY - 2013/4/5

Y1 - 2013/4/5

N2 - Background: Several studies have reported that clinical practice guidelines (CPGs) in a variety of clinical areas are of modest or variable quality. The objective of this study was to evaluate the quality of an international cohort of CPGs that provide recommendations on pharmaceutical management of glycemic control in patients with type 2 diabetes mellitus (DM2). Methods and Findings: We searched the National Guideline Clearinghouse (NGC) on February 15th and June 4th, 2012 for CPGs meeting inclusion criteria. Two independent assessors rated the quality of each CPG using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument. Twenty-four guidelines were evaluated, and most had high scores for clarity and presentation. However, scope and purpose, stakeholder involvement, rigor of development, and applicability domains varied considerably. The majority of guidelines scored low on editorial independence, and only seven CPGs were based on an underlying systematic review of the evidence. Conclusions: The overall quality of CPGs for glycemic control in DM2 is moderate, but there is substantial variability among quality domains within and across guidelines. Guideline users need to be aware of this variability and carefully appraise and select the guidelines that they apply to patient care.

AB - Background: Several studies have reported that clinical practice guidelines (CPGs) in a variety of clinical areas are of modest or variable quality. The objective of this study was to evaluate the quality of an international cohort of CPGs that provide recommendations on pharmaceutical management of glycemic control in patients with type 2 diabetes mellitus (DM2). Methods and Findings: We searched the National Guideline Clearinghouse (NGC) on February 15th and June 4th, 2012 for CPGs meeting inclusion criteria. Two independent assessors rated the quality of each CPG using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument. Twenty-four guidelines were evaluated, and most had high scores for clarity and presentation. However, scope and purpose, stakeholder involvement, rigor of development, and applicability domains varied considerably. The majority of guidelines scored low on editorial independence, and only seven CPGs were based on an underlying systematic review of the evidence. Conclusions: The overall quality of CPGs for glycemic control in DM2 is moderate, but there is substantial variability among quality domains within and across guidelines. Guideline users need to be aware of this variability and carefully appraise and select the guidelines that they apply to patient care.

UR - http://www.scopus.com/inward/record.url?scp=84875965747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875965747&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0058625

DO - 10.1371/journal.pone.0058625

M3 - Article

C2 - 23577058

AN - SCOPUS:84875965747

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e58625

ER -